Strategy and Control of Antimicrobial Therapy Program Implementation at the B.V. Petrovsky National Research Center of Surgery

The introduction of local programs for the rational use of antibiotics in a multidisciplinary hospital is aimed at reducing the level of antibiotic resistance and the frequency of healthcare associated infections (HAI). The aim of the study was to analyze the frequency of infectious complications caused by pathogens with multidrug resistance and the level of resistance at the B.V. Petrovsky National Research Center of Surgery based on the implementation of the SCAT program. Material and methods. A retrospective analysis of the SCAT program implementation results on the basis of the B.V. Petrovsky National Research Center of Surgery was carried out. 1850 case histories of the surgical profile for 2018 were analyzed (male —1095, average age 56.2±14.9 years; female — 755, average age 53.7±11.9 years) and 1502 case histories for the January–October period for 2019 (male — 1114, average age 58.3±12.1 years, and female — 388, average age 55.4±12.6 years). Results. The incidence of HAI in 2018 and 2019 was 354 and 159 cases, respectively. Of these, the incidence of nosocomial pneumonia (NP) was 64 cases (61.5%) and 40 cases (38.5%); skin and soft tissue infection (SSTI) — 93 cases (57.4%) and 69 cases (42.6%); surgical site infections (SSI) — 69 cases (82.1%) and 15 cases (17.9%) in 2018 and 2019, respectively. The drug resistance index (DRI) for the most clinically significant strains of the causative agents of HAI was: Klebsiella pneumoniae — 0.14, Acinetobacter baumannii — 0.22, Klebsiella spp. — 0.11, Enterobacter cloacae — 0.15, Enterococcus faecalis — 0.18, Enterococcus faecium — 0.21. Conclusion. The proposed measures for the implementation of the SCAT program at the level of a medical organization reduce the incidence of HAI and the local level of the drug resistance index.

1. Vsemirnaya organizatsiya zdravookhraneniya. Global-nyj plan dejstvij po bor-be s ustojchivost-jyu k protivomikrobnym preparatam. Zheneva, Shvejtsariya. 2016; 40. [in Russian]

2. Polozheniya Politicheskoj deklaratsii zasedaniya vysokogo urovnya General-noj Assamblei po probleme ustojchivosti k protivomikrobnym preparatam, prinyatoj na 71-j sessii General-noj Assamblei Organizatsii Ob#edinennykh Natsij (rezoljyutsiya A/RES/71/3 ot 5 oktyabrya 2016 g.). [in Russian]

3. Rasporyazhenie Pravitel-stva Rossijskoj Federatsii ot 25 sentyabrya 2017 g. № 2045-r «O Strategii preduprezhdeniya rasprostraneniya antimikrobnoj rezistentnosti v RF na period do 2030 g». [in Russian]

4. Dellit T.H., Owens R.C., McGowan J.E., Gerding D.N, Weinstein R.A., Burke J.P. et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Antimicrobial Stewardship Guidelines. CID 2007; 44: 159–1778.

5. Yakovlev S.V., Briko N.I., Sidorenko S.V., Protsenko D.N. Programma SKAT (Strategiya Kontrolya Antimikrobnoj Terapii) pri okazanii statsionarnoj meditsinskoj pomoshchi Rossijskie klinicheskie rekomendatsii. M.: 2018; 1–156. [in Russian]

6. Eliseeva E.V., Gajnullina Jyu.I., Gel-tser B.I. Upravlenie kachestvom v sfere primeneniya antibakterial-nykh preparatov. Vladivostok: Dal-nauka, 2010; 180. [in Russian]

7. Aslanov B.I., Zueva L.P., Kolosovskaya E.N. Printsipy organizatsii perioperatsionnoj antibiotikoprofilaktiki v uchrezhdeniyakh zdravookhraneniya. Federal-nye klinicheskie rekomendatsii. M.: 2014; 1–42. [in Russian]

8. Bratzler D.W., Dellinger E.P., Olsen K.M., Perl T.M., Auwaerter P.G., Bolon M.K. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surgical infections 2013; 14 (1): 73–156.

9. PRAC: Selexipag Under Review, Starts Antibiotic Safety Review, Megan Brooks, February 10, 2017. Available from: URL: https://www.medscape.com/viewarticle/875648

10. Manikal V.M., Landman D., Saurina G. et al. Endemic carbapenemresistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31: 101–106.

11. Saurina G., Quale J.M., Manikal V.M. et al. Antimicrobial resistance in Enterobacteriacea in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother 2000; 45: 895–898.

12. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. 2016. Available from: URL: https://www.fda.gov/drugs/drug-safety-and-availability/fdadrug-safety-communication-fda-advises-restricting-fluoroquinoloneantibiotic-use-certain

13. Rodríguez-Baño J., Picón E., Gijón P. et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-betalactamase-producing Escherichia coli. J Clin Microbiol 2010; 48: 1726–1731.

14. Ventola C.L. The antibiotic resistance crisis: part 1: causes and threats. PT 2015; 40 (4): 277–283.

15. Hoffman S.J., Caleo G.M., Daulaire N. et al. Strategies for achieving global collective action on antimicrobial resistance. Bull World Health Organ 2015; 93 (12): 867–876.